Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Apr 1.

Published in final edited form as: Arterioscler Thromb Vasc Biol. 2021 Jan 21;41(4):e185–e192. doi: 10.1161/ATVBAHA.120.315737

Figure 2. — (A) A representative lateral view of the μPET maximum-intensity projection (pseudo-color) superimposed on the μCT image of the skeleton in the control and pravastatin-treated mice at baseline (wk 0), mid-treatment (wk 10), and post-treatment (wk 20). (B) MicroCT analysis of aortic calcium content in the control (n = 18) and pravastatin-treated (n = 16) mice. (C) MicroPET analysis of aortic ¹⁸F-NaF uptake in the control (n = 17) and pravastatin-treated (n = 17) mice. *p = 0.03 (Control wk 10 vs. wk 0), **p = 0.02 (Pravastatin wk 20 vs. wk 10). (D) Fold-change in ¹⁸F-NaF uptake over the first 10-wk period (wk 10 vs. wk 0) in the control (n = 17) and pravastatin-treated (n = 17) mice. (E) Fold change in ¹⁸F-NaF uptake over the second 10-wk period (wk 20 vs. wk 10) in the control (n = 17) and pravastatin-treated (n = 17) mice.

Figure 2. — (A) A representative lateral view of the μPET maximum-intensity projection (pseudo-color) superimposed on the μCT image of the skeleton in the control and pravastatin-treated mice at baseline (wk 0), mid-treatment (wk 10), and post-treatment (wk 20). (B) MicroCT analysis of aortic calcium content in the control (n = 18) and pravastatin-treated (n = 16) mice. (C) MicroPET analysis of aortic ¹⁸F-NaF uptake in the control (n = 17) and pravastatin-treated (n = 17) mice. *p = 0.03 (Control wk 10 vs. wk 0), **p = 0.02 (Pravastatin wk 20 vs. wk 10). (D) Fold-change in ¹⁸F-NaF uptake over the first 10-wk period (wk 10 vs. wk 0) in the control (n = 17) and pravastatin-treated (n = 17) mice. (E) Fold change in ¹⁸F-NaF uptake over the second 10-wk period (wk 20 vs. wk 10) in the control (n = 17) and pravastatin-treated (n = 17) mice.